News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Actinogen Medical.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: ASX ‘Magnificent Seven’ rides high amidst the US healthcare mayhem
Health & Biotech
Top of mind: ASX companies tackling neurological disorders
Health & Biotech
Health Check: Star biotech stocks are going cheap – or cheaper than they were
Health & Biotech
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Health & Biotech
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Health & Biotech
Health Check: Hold the front page for a rush of clinical trial updates
Health & Biotech
Health Check: Thirsty Chimeric goes to the well for funding top-up
Health & Biotech
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees
News
Closing Bell: Uranium stocks surge as crunch looms; Actinogen, Kalina lead ASX gains
News
ASX Small Caps Lunch Wrap: US Fed says ‘it’s time’ to cut rates, uranium stocks go flying
Health & Biotech
ASX Health Stocks: Actinogen skyrockets 125pc on antidepressant drug trial results
News
Top 10 at 11: Gas powered AI, happy pills, antimony and gold are today’s hot news
News
ScoPo’s Powerplays: ASX health stocks rise as ‘Pro Medicus again hit the ball out of the park’
Health & Biotech
ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief
Experts
Dr Boreham’s Crucible: In the Alzheimer’s treatment Olympics, this Aussie biotech is a chance of gold
Health & Biotech
Check Up: Aussie biotech Ternarx to pioneer next-gen cancer medicine, and recent ASX health winners
Health & Biotech
